New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer

被引：0
作者：
Bardia, Aditya [1 ,2 ]
机构：
[1] Breast Canc Res Program, Boston, MA 02115 USA
[2] Harvard Med Sch, Med Oncol, Massachusetts Gen Hosp, Boston, MA 02115 USA
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：723 / 725
页数：3
相关论文
共 50 条
  • [21] Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
    Hanna, Daire
    Merrick, Sophie
    Ghose, Aruni
    Devlin, Michael John
    Yang, Dorothy D.
    Phillips, Edward
    Okines, Alicia
    Chopra, Neha
    Papadimatraki, Elisavet
    Ross, Kirsty
    Macpherson, Iain
    Boh, Zhuang Y.
    Michie, Caroline O.
    Swampillai, Angela
    Gupta, Sunnia
    Robinson, Tim
    Germain, Lewis
    Twelves, Chris
    Atkinson, Charlotte
    Konstantis, Apostolos
    Riddle, Pippa
    Cresti, Nicola
    Naik, Jay D.
    Borley, Annabel
    Guppy, Amy
    Schmid, Peter
    Phillips, Melissa
    BRITISH JOURNAL OF CANCER, 2024, 130 (12) : 1916 - 1920
  • [22] The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
    Michaleas, S.
    Oliver, A. Moreno
    Mueller-Berghaus, J.
    Sarac, S. B.
    van der Elst, M. E.
    Mueller-Egert, S.
    Zander, H.
    Enzmann, H.
    Pignatti, F.
    ESMO OPEN, 2022, 7 (03)
  • [23] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
    Schoellmann, Claudia
    BREAST CARE, 2022, 17 (01)
  • [24] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    Brufsky, Adam
    Cortes, Javier
    Loibl, Sibylle
    Piccart, M.
    Cowden, Janice
    Spears, Patty
    Carey, Lisa A.
    FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
  • [25] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
    Carrion-Madronal, Isabel Maria
    Diaz-Acedo, Rocio
    Lora-Escobar, Santiago Jose
    Naranjo-Llamas, Eloisa
    Jaramillo-Ruiz, Didiana
    Artacho-Criado, Silvia
    Prado-Mel, Elena
    FUTURE ONCOLOGY, 2024, 20 (33) : 2565 - 2572
  • [26] Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
    Weiss, Jennifer
    Glode, Ashley
    Messersmith, Wells A.
    Diamond, Jennifer
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (08) : 673 - 679
  • [27] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
    Sathe, Abhishek G.
    Singh, Indrajeet
    Singh, Pratap
    Diderichsen, Paul M.
    Wang, Xiaohui
    Chang, Peter
    Taqui, Atiya
    Phan, See
    Girish, Sandhya
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2024, 63 (05) : 669 - 681
  • [28] Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
    Rossi, Valentina
    Turati, Alessandra
    Rosato, Antonio
    Carpanese, Debora
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [29] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
    Abhishek G. Sathe
    Indrajeet Singh
    Pratap Singh
    Paul M. Diderichsen
    Xiaohui Wang
    Peter Chang
    Atiya Taqui
    See Phan
    Sandhya Girish
    Ahmed A. Othman
    Clinical Pharmacokinetics, 2024, 63 : 669 - 681
  • [30] Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore
    Cher, Boon Piang
    Goh, Sharon
    Aziz, Mohamed Ismail Abdul
    Wong, Grace
    Hui, Raymond Ng Chee
    Ong, Benjamin Shao-Kiat
    Ng, Kwong-Hoe
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (02) : 217 - 225
12345